GSK (GSK) announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has recommended expanding the indication of its adjuvanted recombinant respiratory syncytial virus, RSV, vaccine to all adults aged 18 years and older. The European Commission’s final decision is expected in February 2026. If approved, the expanded indication would make the vaccine available for all adults aged 18 years and older.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- Blujepa approved by FDA as oral option for treatment of urogenital gonorrhea
- GSK price target raised to 1,500 GBp from 1,200 GBp at HSBC
- GSK announces GSK’277 received ODD from FDA to treat SCLC
- Ideaya disclosed termination of GSK license agreement
- GSK price target raised to 1,700 GBp from 1,500 GBp at JPMorgan